University of Chicago researchers assessed the long-term health outcomes and cost-effectiveness of four antiobesity medications compared to lifestyle modification alone. Results indicate that tirzepatide and semaglutide provide substantial health benefits, including reductions in obesity, diabetes, and cardiovascular disease cases. However, high treatment costs can render these medications economically inefficient under current pricing.
This article was originally published on MedicalXpress.com